Drugging RNA–Protein Complexes with Small Molecules to Enable RNA Splice Modulation & Degradation
• REM-422 is being developed by Remix Therapeutics for the treatment of ACC and AML/HRMDS
• REMaster™ platform identifies compounds that address undruggable high unmet medical need targets
• Next generation Remix drug discovery programs are enabled by a suite of biophysical assays and expand the scope of pharmacologically tractable splice modulator modalities